These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Acute effects of air pollution on peak expiratory flow rates and symptoms among asthmatic patients in Chiang Mai, Thailand.
    Author: Wiwatanadate P, Liwsrisakun C.
    Journal: Int J Hyg Environ Health; 2011 Jun; 214(3):251-7. PubMed ID: 21530391.
    Abstract:
    The open burnings and forest fires have been recognized as the major sources of severe air pollution in the upper north of Thailand; however, there have been no clear evidences to show the associations between the air pollution and health effects in the area. We assessed the effects of air pollutants on the peak expiratory flow rates (PEFR) and symptoms in asthmatics. A cohort of 121 asthmatics was followed daily, for 306 days, for their PEFR and asthma symptoms. The daily air pollutants, including particulate matter with aerodynamic diameter <2.5 μm, particulate matter with aerodynamic diameter <10 μm (PM(10)), carbon monoxide, ozone, nitrogen dioxide (NO(2)), and sulfur dioxide (SO(2)), and the meteorological parameters, including pressure, temperature, relative humidity, rain quantity, and sunshine duration, were monitored. The PEFRs were fitted with general linear mixed models. The asthma symptoms were analyzed with the generalized estimating equations. There were positive associations of NO(2) with morning PEFR, with a coefficient of 0.06 [95% confidence interval (CI), 0.00-0.12]; of SO(2) with evening PEFR [with a range of coefficients of 0.88-1.00 (95% CI, 0.31-1.54)] and daily average PEFR [with a coefficient of 0.47 (95% CI, 0.00-0.94)]; of PM(10) with evening PEFR, with a coefficient of 0.02 (95% CI, 0.00-0.04). There was also negative association of PM(10) with ΔPEFR, with a coefficient of -0.01 (95% CI, -0.01 to -0.00). No pollutants were related to asthma symptoms. More studies are needed, particularly at low dose in adult asthmatics, to validate our findings.
    [Abstract] [Full Text] [Related] [New Search]